Showing 2621-2630 of 3570 results for "".
- To Keep Pace with Growth, Crown Builds Out Manufacturing Complexhttps://practicaldermatology.com/news/to-keep-pace-with-growth-crown-builds-out-manufacturing-complex/2461266/Crown Laboratories is adding 60,000 square feet to its manufacturing complex in Johnson City, TN. The facility is home to PanOxyl acne wash, Blue Lizard Australian Sunscreen, and Sarna anti-itch lotion. The additional 60,000 sq. ft. will bring the Lafe Cox Drive facility
- Cynosure's New Tempsure eyeEnvi Handpiece Offers Improved Function and Greater Comforthttps://practicaldermatology.com/news/cynosures-new-tempsure-eyeenvi-handpiece-offers-improved-function-and-greater-comfort/2461258/Cynosure has added a new Tempsure eyeEnvi handpiece to its portfolio. Featuring innovative ergonomic pencil grip design and lighter piston tension required to activate the treatment, the company says the new handpiece is more comfortable for patients and providers, heating thinner tissue mor
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri
- Researchers ID Sensor Underlying Mechanical Itchhttps://practicaldermatology.com/news/researchers-id-sensor-underlying-mechanical-itch/2461248/Scientists at Scripps Research have identified a protein in sensory nerves that works as a key detector of the “mechanical” itch stimulus of crawling insects, wool fibers, or other irritating objects that touch the skin. The discovery, published June 22, 2022, in Nature
- TruSkin SPF 30 Mineral Sunscreen with Vitamin C Launcheshttps://practicaldermatology.com/news/truskin-spf-30-mineral-sunscreen-with-vitamin-c-launches/2461245/New from TruSkin, TruSkin SPF 30 Mineral Sunscreen with Vitamin C features non-nano zinc oxide in a lightweight, non-greasy formula with asheer finish intended to blend into a
- FDA Approves Dupixent for Children 6 Months to 5 Years with Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis/2461224/The FDA has approved Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab) for children aged 6 months to 5 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regu
- Message from ASLMS President Dr. Paul M. Friedmanhttps://practicaldermatology.com/news/message-from-aslms-president-dr-paul-m-friedman/2461221/Dr. Paul M. Friedman, president of the American Society for Laser Medicine and Surgery (ASLMS), is calling on members to expand philanthropic programs that can help change lives with lasers. “In the coming year, I will be looking to the membership to bring their talents forwa
- University of Bradford Propels Skin Microbiome Researchhttps://practicaldermatology.com/news/university-of-bradford-propels-skin-microbiome-research/2461219/University of Bradford scientists are helping open new areas of research into the skin microbiome. Much like the gut microbiome, the skin has its own community of microorganisms, whose job is to protect us from infection and maintain a healthy state. However, scientists are only now beg
- FDA Accepts sBLA for Priority Review for Dupixent in PNhttps://practicaldermatology.com/news/fda-accepts-sbla-for-priority-review-for-dupixent-in-pn/2461218/FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) from Sanofi and Regeneron to treat adults with prurigo nodularis. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by dat
- Verrica Receives Complete Response Letter from FDA for NDA for VP-102https://practicaldermatology.com/news/verrica-receives-complete-response-letter-from-fda-for-nda-for-vp-102/2461214/The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc.'s New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). According to the company, the only deficiency listed in the CRL was related to the deficiencies